ProMIS Neurosciences is trading at $8.65, up 5.1%, amid broader biotech-sector strength; no confirmed company-specific catalyst has emerged. - Biotech ETF XBI was up 2.10% during regular trading, alongside the stated sector rally. - No new company-specific announcement explaining the October 20 move surfaced in the search. - ProMIS is scheduled to participate in Chardan’s 10th Annual Healthcare Conference at 2 p.m. EDT.